

PHARMACEUTICAL 2023

Guardion Health Sciences Inc. Rank 252 of 446









PHARMACEUTICAL 2023



Guardion Health Sciences Inc. Rank 252 of 446

The relative strengths and weaknesses of Guardion Health Sciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Guardion Health Sciences Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Guardion Health Sciences Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 51%, being 8.0% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	21,637
Cost of Goods Sold	6,529
Intangible Assets	0
Liabilities, Current	4,012
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	12,169
Other Liabilities	4,507
Other Net Income	2,498
Other Revenues	11,050
Property and Equipment	49
Research and Development	194
Selling, General and Administrative Expense	9,578

Output Variable	Value in 1000 USD
Assets	21,686
Liabilities	8,518
Expenses	28,470
Revenues	11,050
Stockholders Equity	13,168
Net Income	-14,922
Comprehensive Net Income	-14,922
Economic Capital Ratio	51%

